Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany

Abstract Introduction While golimumab (GLM) has demonstrated efficacy in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in several randomized clinical trials with biologic-naïve patients, observational data from biologic-experienced patients are sparse. We aime...

Full description

Bibliographic Details
Main Authors: Klaus Krüger, Gerd Rüdiger Burmester, Siegfried Wassenberg, Matthias H. Thomas
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-04-01
Series:Rheumatology and Therapy
Subjects:
Ankylosing spondylitis
First-line/second-line/third-line treatment
Golimumab
Noninterventional study
Psoriatic arthritis
Real-world evidence
Online Access:https://doi.org/10.1007/s40744-020-00204-9

Internet

https://doi.org/10.1007/s40744-020-00204-9

Similar Items